Compare EQS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQS | MRKR |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | EQS | MRKR |
|---|---|---|
| Price | $1.31 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.17 |
| AVG Volume (30 Days) | 24.9K | ★ 359.0K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,377,000.00 | ★ $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.11 | N/A |
| 52 Week Low | $0.74 | $0.81 |
| 52 Week High | $2.49 | $4.07 |
| Indicator | EQS | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 25.99 | 73.26 |
| Support Level | $1.27 | $1.45 |
| Resistance Level | $1.44 | $1.55 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 9.32 | 66.94 |
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.